Clinical efficacy and future prospects of immunotherapy in lung cancer

Tomonari Kinoshita, Hideki Terai, Tomonori Yaguchi

Research output: Contribution to journalReview articlepeer-review

Abstract

The three major conventional treatments: surgery, chemotherapy, and radiation therapy, have been commonly performed for lung cancer. However, lung cancer is still the leading cause of cancer-related mortality. Immunotherapy has recently emerged as a very effective new treatment modality, and there is now growing enthusiasm for cancer immunotherapy worldwide. However, the results of clinical studies using immunotherapy are not always favorable. Understanding the steps involved in the recognition and eradication of cancer cells by the immune system seems essential to understanding why past immunotherapies have failed and how current therapies can be optimally utilized. In addition, the combination of immunotherapies, such as cancer vaccines and immune checkpoint inhibitors, as well as the combination of these therapies with three conventional therapies, may pave the way for personalized immunotherapy. In this review, we summarize the results of immunotherapies used in phase III clinical trials, including immune checkpoint inhibitors, and discuss the future prospects of immunotherapies in lung cancer treatment.

Original languageEnglish
Article number1029
JournalLife
Volume11
Issue number10
DOIs
Publication statusPublished - 2021 Oct
Externally publishedYes

Keywords

  • Immune checkpoint inhibitor
  • Immunotherapy
  • Lung cancer

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Biochemistry, Genetics and Molecular Biology(all)
  • Space and Planetary Science
  • Palaeontology

Fingerprint

Dive into the research topics of 'Clinical efficacy and future prospects of immunotherapy in lung cancer'. Together they form a unique fingerprint.

Cite this